Kodiak Sciences Inc

K27

Company Profile

  • Business description

    Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

  • Contact

    1250 Page Mill Road
    Palo AltoCA94304
    USA

    T: +1 650 281-0850

    E: [email protected]

    https://www.kodiak.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    124

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,187.2017.30-0.19%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,835.44197.840.84%
NASDAQ25,136.27229.82-0.91%
Nikkei 22560,042.511,099.84-1.80%
NZX 50 Index14,274.92101.240.71%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,066.1016.10-0.18%
SSE Composite Index3,620.0014.35-0.39%

Market Movers